1,238 Spam-Free Article(s) Found
Sort:
Like
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Wednesday’s Close
ONCE Spark Therapeutics, Inc. $57.05 $2.14B N/A
Article Searches
WPX Energy Monetizes Midstream Assets Once Again for $350M http://www.zacks.com/stock/news/370188/wpx-energy-monetizes-midstream-assets-once-again-for-%24350m?cid=CS-ZC-FT-370188 Apr 03, 2019 - WPX Energy's (WPX) subsidiary and joint venture partner in the Oryx II pipeline sign agreements to monetize its 25% interest in the Oryx II pipeline for $350 million.
4 Gene Therapy Players Likely to Become Buyout Targets in 2019 http://www.zacks.com/stock/news/372303/4-gene-therapy-players-likely-to-become-buyout-targets-in-2019?cid=CS-ZC-FT-372303 Apr 08, 2019 - Gene therapy continues to be in focus given the recent spate of deals and acquisitions. We highlight four stocks, which have promising gene therapy candidates in their pipeline.
Ophthotech Gets Rights to Gene Therapy for BEST Disease http://www.zacks.com/stock/news/379738/ophthotech-gets-rights-to-gene-therapy-for-best-disease?cid=CS-ZC-FT-379738 Apr 12, 2019 - Ophthotech (OPHT) obtains development/commercialization rights to AAV gene-therapy program for BEST1-related retinal diseases from Penn and UFRF.
Roche Gets FDA Nod for Expansion of Cobas 6800/8800 Systems http://www.zacks.com/stock/news/419984/roche-gets-fda-nod-for-expansion-of-cobas-6800-8800-systems?cid=CS-ZC-FT-419984 May 27, 2019 - Roche (RHHBY) gets FDA clearance for the expansion of its leading testing menu.
Roche Receives FTC Request for Further Data on Spark Buyout http://www.zacks.com/stock/news/427145/roche-receives-ftc-request-for-further-data-on-spark-buyout?cid=CS-ZC-FT-427145 Jun 10, 2019 - Roche (RHHBY) gets additional information request from FTC for the pending Spark acquisition.
American Airlines Extends 737 MAX Grounding Period Once More http://www.zacks.com/stock/news/427232/american-airlines-extends-737-max-grounding-period-once-more?cid=CS-ZC-FT-427232 Jun 10, 2019 - American Airlines (AAL) extends 737 MAX cancellation period through Sep 3. Approximately, 115 flights are likely to be cancelled each day during the time frame.
ETFs Poised to Benefit from Gene Editing Revolution http://www.zacks.com/stock/news/505549/etfs-poised-to-benefit-from-gene-editing-revolution?cid=CS-ZC-FT-etf_news_and_commentary-505549 Sep 06, 2019 - Rising investments and growing technological advancement are favoring the genomic editing space. We take a look at a few ETFs that can cash in on this trend.
Roche's (RHHBY) Rituxan Receives FDA Nod for Label Expansion http://www.zacks.com/stock/news/542716/roches-rhhby-rituxan-receives-fda-nod-for-label-expansion?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-542716 Sep 30, 2019 - Roche (RHHBY) gets FDA approval for Rituxan to treat children with two rare blood vessel disorders. The company also extends the offer period to acquire Spark Therapeutics.
Spark Therapeutics Stock Plunges on Hemophilia Therapy Data http://www.zacks.com/stock/news/285686/spark-therapeutics-stock-plunges-on-hemophilia-therapy-data?cid=CS-ZC-FT-285686 Dec 12, 2017 - Spark Therapeutics (ONCE) plunged 35% as investors were not impressed by the data from a phase I/II study on its Hemophilia A candidate, SPK-8011.
Biotech Stock Roundup: Label Expansion for Exelixis's Cabometyx, FDA Nod for Spark's Gene Therapy http://www.zacks.com/stock/news/286464/biotech-stock-roundup-label-expansion-for-exelixiss-cabometyx-fda-nod-for-sparks-gene-therapy?cid=CS-ZC-FT-286464 Dec 20, 2017 - A one-time gene therapy for an inherited retinal disease gained FDA approval this week while Exelixis's (EXEL) Cabometyx can now be used in treatment-naive advanced renal cell carcinoma patients.
<<<Page 121>